Fig. 1: Proliferative fraction dynamics in the IOSI-EMA-001 trial. | Leukemia

Fig. 1: Proliferative fraction dynamics in the IOSI-EMA-001 trial.

From: Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia

Fig. 1

A Gating strategy for proliferative (PF, CXCR4dim/CD5bright, red) and resting (RF, CXCR4bright/CD5dim, green) populations by flow cytometry of a representative CLL case in the IOSI cohort. Populations were tracked using a fixed-gate strategy. Reported are percentage of each population over the entire CD19 + /CD5 + CLL population and the month of sampling under ibrutinib. Trend of the proliferative fraction (PF, B) and resting fraction (RF, C) over time by month under ibrutinib. ***p ≤ 0.001 by two-sided Mann–Whitney rank-test compared to month zero. Only significant comparisons are reported. Red dots indicate samples collected from patients close to clinical progression. D Heatmap summarizing the row-normalized median value of investigated features over the cohort: percentage of parent population for PF/RF, mean fluorescence intensity for CXCR4, CD5, and CD20.

Back to article page